scholarly journals Economic survivorship stress is associated with poor health-related quality of life among distressed survivors of hematopoietic stem cell transplantation

2012 ◽  
Vol 22 (4) ◽  
pp. 911-921 ◽  
Author(s):  
Jada G. Hamilton ◽  
Lisa M. Wu ◽  
Jane E. Austin ◽  
Heiddis Valdimarsdottir ◽  
Katie Basmajian ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Health Related Quality ◽  
Hematopoietic Stem ◽  
Related Quality ◽  
Health Related

Oral health-related quality of life before hematopoietic stem cell transplantation

2015 ◽  
Vol 19 (9) ◽  
pp. 2345-2349 ◽  
Author(s):  
J. E. Tinoco-Araujo ◽  
E. S. L. Orti-Raduan ◽  
D. Santos ◽  
V. A. R. Colturato ◽  
M. P. Souza ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Stem Cell ◽  
Oral Health ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Health Related Quality ◽  
Hematopoietic Stem ◽  
Related Quality ◽  
Health Related

scholarly journals Health-Related Quality of Life Following Allogeneic Hematopoietic Stem Cell Transplantation

Hematology ◽  
2010 ◽  
Vol 2010 (1) ◽  
pp. 248-254 ◽  
Author(s):  
Margaret Bevans
Keyword(s):  
Quality Of Life ◽  
Stem Cell ◽  
Clinical Practice ◽  
Hematopoietic Stem Cell Transplantation ◽  
Health Related Quality ◽  
Hematopoietic Stem ◽  
Allogeneic Hsct ◽  
Related Quality ◽  
Health Related

Abstract It is common knowledge that an allogeneic hematopoietic stem cell transplantation (HSCT) will have an enormous impact on the lives of transplant recipients and their families. Once an appropriate donor is identified, the curative potential of this treatment often drives the decision to proceed knowing that there will be intense physiologic toxicities and adverse effects on health-related quality of life (HRQL). Twenty-five years ago, HRQL was identified as an efficacy parameter in the evaluation of new anticancer drug therapy. Overall, the evidence suggests that an allogeneic HSCT has a significant impact on the overall HRQL of recipients, which is a result of decrements across all dimensions, including a significant symptom profile. The degree of impact on overall HRQL and the multiple dimensions varies across the transplant trajectory. Specific HRQL dimensions, such as physical function and symptoms, are easily incorporated into a clinician's assessment whereas other dimensions (eg, psychosocial) are less commonly integrated. The translation of HRQL results to improve clinical practice is not well established. Clinicians are often uncertain when to assess the scope of HRQL and how to interpret the information in a clinically meaningful way. The purpose of this review is to highlight the quality-of-life effects of allogeneic HSCT and discuss application into clinical practice.

Health-Related Quality of Life 1 Year After Allogeneic or Autologous Stem-Cell Transplantation: A Prospective Study

1999 ◽  
Vol 17 (2) ◽  
pp. 706-706 ◽  
Author(s):  
Marianne J. Hjermstad ◽  
Stein A. Evensen ◽  
Stein O. Kvaløy ◽  
Peter M. Fayers ◽  
Stein Kaasa
Keyword(s):  
Quality Of Life ◽  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Sleep Disturbances ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related

PURPOSE: To evaluate health-related quality of life (HRQOL) in adults treated with high-dose chemotherapy followed by allogeneic (SCT) and autologous (ASCT) stem-cell transplantation 1 year after transplantation, using data from concurrent lymphoma patients receiving combination chemotherapy (CT) as a reference. MATERIALS AND METHODS: Forty-one leukemia patients (SCT group), 51 lymphoma patients (ASCT group), and 85 CT patients completed the European Organization for Research and Treatment of Cancer QLQ-C30 questionnaire at baseline and after 1 year. RESULTS: The SCT group (median age, 36 years) had better functioning scores and less symptomatology at baseline compared with the ASCT (median age, 41 years) and CT (median age, 37 years) groups. Statistically significant differences of 10 or more points on the 0 to 100 scales were found for 10 of 15 scales and items (P ≤ .01) between the SCT and ASCT groups. Global quality of life (79 v 58, P < .0001), role function (83 v 65, P = .001), sleep disturbances (6 v 28, P < .0001), and fatigue (25 v 44, P = .0001) deviated most. The differences were 10 or more points for seven of 15 scales and items comparing the SCT and CT groups, with sleep disturbances (6 v 35, P < .0001) and pain (11 v 29, P < .01) deviating most. Differences across groups were smaller after 1 year; cognitive function was the only scale with a statistically significant difference (ASCT 80 v CT 89; P = .002). Patterns of change in HRQOL scores were different between groups during follow-up. A great improvement was found in the ASCT group (P < .01 for emotional and role function, fatigue, appetite, and constipation), whereas no significant changes were observed for the SCT group. CONCLUSION: Prospective studies with extended follow-up periods are necessary to separate a slow recovery process from more permanently reduced HRQOL after transplantation and to examine the late side effects from previous treatment.

Sign in / Sign up

Export Citation Format

Share Document